Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
TMUS$157.48-2.67(-1.67%)T-Mobile Brings More to the Holiday Mix: Deals on the Season’s Must-Have Tech, All-New T-Mix Plans and More9:36:02 AM ETCRM$214.92-11.18(-4.94%)Salesforce Climbs 22% in Six Months: Is the Stock Still Worth Buying?9:31:07 AM ETSAN$11.48+0.02(+0.17%)World faces €30 trillion financing gap, Santander report warns9:31:03 AM ETNET$271.31+6.21(+2.34%)JPMorgan upgrades Cloudflare (NET) to Overweight after selloff9:26:24 AM ETINTC$61.83+1.88(+3.14%)Intel Drops 31% in a Day as Data Center Sales Jump 78%9:14:00 AM ETPFE$31.02+0.32(+1.04%)Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction9:13:02 AM ETPLTR$170.85-7.51(-4.21%)Burry vs Karp: One Year Later, Who Actually Won the Palantir Fight?9:06:03 AM ETGOOGL$278.72-0.31(-0.11%)Anthropic's Spending Commitments Are Soaring Towards $1 Trillion9:04:14 AM ETHD$334.59-6.59(-1.93%)Home Depot Stock Could Be Poised for a Turnaround. Here's How High It Could Go9:03:58 AM ETPNGAF$0.24+0.04(+17.53%)Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion9:01:24 AM ETLSE:TTE$83.20-1.80(-2.12%)TotalEnergies Marketing USA Signs Supply Agreement with SSF Imported Auto Parts for ELF Passenger Car Motor Oils9:01:19 AM ETPFE$31.02+0.32(+1.04%)Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates9:00:49 AM ETSHOP$140.17-16.03(-10.26%)Shopify Operating Income Jumps 66%: Rapid Earnings Reaction9:00:30 AM ETMU$866.00+32.71(+3.93%)Micron or Nvidia: If I Could Only Buy and Hold One of These Artificial Intelligence (AI) Chip Stocks for the Next 5 Years, It Would Be This One9:00:00 AM ETGEV$909.75+47.30(+5.48%)GE Vernova Is Paying $9 Billion for Trench Group. Here's Why the Grid Is Crucial to the Electricity Supercycle.9:00:00 AM ETSPCX$140.16+3.82(+2.80%)SpaceX stock price 2027 forecast8:59:16 AM ETINTC$61.83+1.88(+3.14%)Intel Q3: What May Happen If 50% Of Total Revenue Declines In Coming Quarters (Upgrade)8:57:44 AM ETPLTR$170.85-7.51(-4.21%)Dan Ives Says Palantir Is Answering AI's Biggest Question: Where's the Money?8:55:03 AM ETGOOG$277.87-0.13(-0.05%)AI Stocks Lose $5 Trillion in 3 Weeks as Hedge Funds Go Underweight AI for the First Time Since 20238:54:17 AM ETFOX$56.33+0.41(+0.73%)Unlike Fox News, MS NOW Is “Not Seeing Any Viewer Fatigue,” Parent Company CEO Mark Lazarus Says8:50:08 AM ETAAPL$329.92-8.67(-2.56%)Apple Retreats 4% Despite Earnings Beat as Memory Costs Squeeze Margin Outlook; Microsoft Dips, Meta Holds Steady8:49:42 AM ETAMD$490.49+24.06(+5.16%)AMD Stock Reports Earnings Today: Here's What Investors Need to Know8:49:16 AM ETSPCX$140.16+3.82(+2.80%)Jim Cramer flags major SpaceX opportunity Wall Street may have missed8:48:00 AM ETSHOP$140.17-16.03(-10.26%)Shopify Plunges 17% as GMV and Subscription Revenue Miss Estimates; Wix Drops 3%, Etsy Dips8:47:37 AM ET

LUCD · NASDAQ

Lucid Diagnostics Inc.

$0.41 0.00 (+0.02%)

Company overview

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory-developed esophageal DNA test, and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ
Market cap
$78.3M
Employees
72
Headquarters
New York City, NY
Website
luciddx.com
CEO
Lishan Aklog
Listed
October 14, 2021
P/E
-0.90
Dividend yield
0.00%

Company financials

Revenue
$5.1M
Gross profit
-$2.1M
Operating income
-$49.3M
EBITDA
-$42.3M
Net income
-$45M
EPS
-$0.47
Total assets
$34.1M
Total debt
$26.8M
Gross margin
-40.03%
Net margin
-876.72%
Earnings yield
-110.90%

Price chart

0.270.520.761.011.26
LUCD 1D NASDAQ O0.41H0.41L0.39C0.41+0.01 (+1.26%)Vol901.57K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
LUCDLucid Diagnostics Inc. Press release Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiar… PR Newswire
LUCDLucid Diagnostics Inc. Press release PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026 PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical… PR Newswire
LUCDLucid Diagnostics Inc. Press release Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 Lucid Diagnostics Inc. PR Newswire
LUCDLucid Diagnostics Inc. Press release Oil Above $100 Puts Penny Stocks in Focus GlobeNewswire
LUCDLucid Diagnostics Inc. Press release Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing Lucid Diagnostics Inc. PR Newswire
LUCDLucid Diagnostics Inc. Press release Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways PR Newswire
LUCDLucid Diagnostics Inc. Press release PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results PRNewsWire
LUCDLucid Diagnostics Inc. Stock news Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript Seeking Alpha
LUCDLucid Diagnostics Inc. Stock news Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates Zacks Investment Research
LUCDLucid Diagnostics Inc. Press release PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results PRNewsWire
LUCDLucid Diagnostics Inc. Stock news Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript Seeking Alpha
LUCDLucid Diagnostics Inc. Stock news Lucid Diagnostics Q1 Earnings Call Highlights MarketBeat
LUCDLucid Diagnostics Inc. Stock news Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates Zacks Investment Research
LUCDLucid Diagnostics Inc. Press release Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results PRNewsWire
LUCDLucid Diagnostics Inc. Stock news Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks Investment Research
LUCDLucid Diagnostics Inc. Press release PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026 PRNewsWire
LUCDLucid Diagnostics Inc. Press release Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026 PRNewsWire
LUCDLucid Diagnostics Inc. Press release Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock PRNewsWire
LUCDLucid Diagnostics Inc. Press release Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock PRNewsWire
LUCDLucid Diagnostics Inc. Stock news Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of “Moderate Buy” from Analysts Defense World
See more
FAQ

Questions about Lucid Diagnostics Inc.

What does Lucid Diagnostics Inc. do?
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory-developed esophageal DNA test, and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
What is LUCD's market cap?
Lucid Diagnostics Inc. (LUCD) is a listed stock with a live quote. The latest market cap on this page is $78.3M.
Where is Lucid Diagnostics Inc. headquartered?
Lucid Diagnostics Inc. is headquartered in New York City, NY.
How do I get LUCD news from the API?
Call GET /v1/news?tickers=LUCD. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does LUCD news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for LUCD, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the LUCD price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs